A Randomised, Multicentre, 48 Week Trial of Maraviroc With or Without Metformin for Hepatic Steatosis in HIV-1-infected Adults on Combination Antiretroviral Therapy
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Maraviroc (Primary) ; Metformin (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms MAVMET
Most Recent Events
- 03 Nov 2021 Status changed from active, no longer recruiting to completed.
- 30 Oct 2021 Primary endpoint has not been met. (Change in percentage of liver fat as measured by 1H MRS over 48 weeks)as per results presented at the 18th European AIDS Conference
- 30 Oct 2021 Results presented at the 18th European AIDS Conference